John L. McManus
Chief Executive Officer
John L. McManus. Mr. McManus began as a consultant to the Company in June 2005 as President. He became employed as our President and Chief Operating Officer in July 2006 and was appointed President and Chief Executive Officer in March 2007. Mr. McManus, who received his degree in business administration from the University of Southern California in 1986, is the founder and president of McManus Financial Consultants, Inc. (“MFC”), which provides strategic, financial and investor relations advice to senior managements and boards of directors of public companies, including advice on mergers and acquisitions. These companies have a combined value of over $25 billion. He has served as president of MFC since 1997. In addition, Mr. McManus previously served as Vice President, Finance and Strategic Planning to Spectrum Pharmaceuticals, Inc. where he had primary responsibility for restructuring Spectrum’s operations and finances, including the design of strategic and financial plans to enhance Spectrum’s corporate focus, and leading the successful implementation of these plans. The implementation of these plans led to an increase in Spectrum’s market value from $1 million to more than $125 million at the time of Mr. McManus’ departure.
Brian Day, Ph.D.
Chief Scientific Officer
Dr. Day is a consultant and was appointed Chief Scientific Officer of Aeolus Pharmaceuticals in September 2004. Dr. Day received his PhD in Pharmacology and Toxicology from Purdue University in 1992 and did his post doctoral training at Duke University from 1992 to 1995. He has extensive training in both pharmacology and toxicology with over 18 years of experience. Since 1994 he has helped guide the design and synthesis of metalloporphyrins and has discovered a number of their novel activities in biological systems. Dr. Day has authored over a 100 original scientific publications and served as a consultant to biotechnology companies for over 16 years. He is an active member of a number of scientific societies including the American Chemical Society, American Thoracic Society, Society for Free Radicals in Biology and Medicine, and Society of Toxicology. Dr Day is on the editorial board of Biochemical Pharmacology and was a member of the NIH Lung Injury, Repair and Remodeling Study Section from 2005 to 2009. Dr. Day has been at National Jewish Health since 1997 where he is a Vice Chair and Professor of Medicine. He is one of the scientific co-founders of Aeolus Pharmaceuticals and an inventor on a majority of the catalytic antioxidant program’s patents.
Russell Skibsted
Chief Financial Officer
Russell began consulting for the company in September 2010. Russell is a seasoned executive with over 25 years of experience in finance, acquisitions, partnering, marketing and operations with companies ranging from start-ups to a Fortune 5. He has significant private equity, public market, operations and transaction experience with both public and private companies. Previously he was Sr. Vice President & Chief Business Officer of Spectrum Pharmaceuticals (NASDAQ: SPPI) where he led global strategy, M&A, licensing, fund-raising, & IR/PR. At Spectrum he completed a significant partnership and an asset sale generating over $62 million in non-dilutive funding to the company in 2008, at a time when the capital markets were inaccessible to small-cap biopharma companies. Previously, he was CFO at Hana Biosciences (NASDAQ: HNAB)[now Talon Therapeutics (OTC: TLON.OB)], where he led the process of bringing the company public & completed two financings. Previously, he was Partner and CFO at Asset Management Company, one of the oldest and most respected venture capital firms in the Silicon Valley, where he oversaw the financial & administrative functions, public & private portfolios, & aviation operations.
Christopher Stanley
VP, Operations
Mr. Stanley has been with the company since 2011. He has 22 years of experience in the FDA regulated pharmaceutical / biotech industry, including responsibility for global supply chain management for Spectrum Pharmaceuticals, where he saved the company $2 million per year in operating expenses. Prior to this, he held management positions at Dendreon Corp. and IDEC Pharmaceuticals. Mr. Stanley has extensive expertise in CMC, including oversight of GMP/GLP/GCP (GxP) systems. He has served as Quality/Validation lead for four different companies for multiple FDA inspections. Mr. Stanley has been involved in the development of numerous early and late-stage pharmaceutical/biotech products, as well as BLA/NDA submissions and marketed product launches.